Zentalis shares rise as lead drug extends survival in ovarian cancer trial
Zentalis shares gained after mid-stage data showed azenosertib extended median survival to 15.8 months in a Cyclin E1-positive ovarian cancer subgroup.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Shares of Zentalis Pharmaceuticals rose on Monday after the cancer drug developer reported mid-stage trial data. Its lead candidate, azenosertib, was linked to longer survival in a subset of patients with ovarian cancer. The company said on Sunday, citing a September 2 data cut from Part 1b of the DENALI Phase 2 study, that results were encouraging in that group.
Median overall survival was 15.8 months in the Cyclin E1-positive subgroup, versus 7.5 months in the Cyclin E1-negative subgroup. No new safety signals were reported. The data were posted as an abstract ahead of a rapid oral presentation at the ESMO Congress on Friday. The company said Cyclin E1 is a critical biomarker for response and supports further study in DENALI Part 2 and ASPENOVA.
why it matters
For investors, this news mainly concerns one small biotech company. The data are early and the outcome of later trial phases is unknown, so the market reaction may prove short-lived.
market impact
Zentalis: positive trial data supports interest in the company's shares
tags
instruments
sources
- Zentalis rises as lead asset extends survival in mid-stage trial for ovarian cancer — Seeking Alpha, 19 October 2026 at 18:31 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗